Brii Biosciences Limited
Headquarters country
Cayman Islands
Registry sponsor category
Industry
- Company name
- Brii Biosciences Limited
- Organisation type
- Industry
- Registered legal name
- BRII BIOSCIENCES LIMITED
- Registry sponsor category
- Industry
- Brii Biosciences, Inc.
- Brii Biosciences Limited
- Legal Entity Identifier (LEI)
- 5493000GCQ47MM4EKK44
Related records
Trials (15)
- A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
- A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19
- A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
- A Study of BRII-297 in Healthy Adult Subjects
- A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
- ACTIV-2: A Study for Outpatients With COVID-19
- ACTIV-3: Therapeutics for Inpatients With COVID-19
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
- Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196
- Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
- Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
- Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
- Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection